Eisai stock slumps after Alzheimer’s drug fails to get approval in Europe

Read Time:5 Second

Eisai shares fell sharply after its Alzheimer’s drug failed to secure marketing approval in the European Union.

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

This week’s aggressive Fed rate cut could provide some breathing space for distressed companies, notes one bankruptcy attorney.

It’s that time again: Investors will see option contracts tied to more than $5 trillion in tradeable stocks expire on...

Investors are mulling strategies beyond cash on expectations that interest rates will continue to fall after the Fed’s big rate...

The package-delivery giant said reduced demand for priority services and higher operating costs weighed on results.

Elliott Hill will replace John Donahoe as chief executive next month, following months of struggles for the athletic-wear giant.

Mortgage rates inched up even though the Federal Reserve cut interest rates. Experts explain why this is a short-lived phenomenon.